| Meera Patel, | |
|
1860 Wimbleton Wood Dr, Fort Mill, SC 29708-8463 | |
| (803) 493-9533 | |
| Not Available |
| Full Name | Meera Patel |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1860 Wimbleton Wood Dr, Fort Mill, South Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134519739 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 23901 (North Carolina) | Primary |
| 183500000X | Pharmacist | 35418 (South Carolina) | Secondary |
| Mailing Address | Practice Location Address |
|---|---|
| Meera Patel, 1860 Wimbleton Wood Dr, Fort Mill, SC 29708-8463 Ph: (803) 493-9533 | Meera Patel, 1860 Wimbleton Wood Dr, Fort Mill, SC 29708-8463 Ph: (803) 493-9533 |
News Archive
Italian researchers at the Catholic University of Sacred Heart in Rome found an important molecular mechanism responsible for low back pain and other acute vertebral problems like cervical axial pain, all due to aging and degeneration of the vertebral column.
Researchers at the University of Minnesota have found that cerebral malaria is related to long-term cognitive impairment in one of four child survivors. The research is published in the current issue of the journal Pediatrics.
A new study by Harvard School of Public Health (HSPH) researchers finds a strong association between the consumption of red meat-particularly when the meat is processed-and an increased risk of type 2 diabetes.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to sales of Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma's Remicade, the two emerging TNF-alpha inhibitors Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma/Janssen's Simponi will drive sales of the TNF-alpha inhibitor drug class to nearly triple by 2018 for the treatment of ulcerative colitis.
Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) today announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA(TM) (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology. Both trials succeeded in meeting their primary endpoints, which should make BENLYSTA eligible for approval by the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
Dr. Amanda Witbeck, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 510 Tom Hall St, Fort Mill, SC 29715 Phone: 803-547-5586 | |
Modinat Fadeke Abiodun, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1250 Tom Hall St, Fort Mill, SC 29715 Phone: 803-548-4699 | |
Dr. Emily N Johnson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1750 Highway 160 W, Fort Mill, SC 29708 Phone: 803-396-0450 | |
John D Hoelscher Iii, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 524 Cuxhaven Ct, Fort Mill, SC 29715 Phone: 803-396-0675 | |
Mr. John Earle Turner Jr., RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1741 Silverwood Dr, Fort Mill, SC 29715 Phone: 803-548-2556 Fax: 803-547-5847 | |
Avis Rochelle White, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 510 Tom Hall St, Fort Mill, SC 29715 Phone: 803-547-5586 Fax: 803-547-5695 |